Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Halozyme Therapeutics, Inc.
Baxter and Halozyme Announce Completion of Patient Enrollment in Phase III Pivotal Trial of GAMMAGARD LIQUID™ with rHuPH20 Enzyme
July 27th, 2009
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc. (Nasdaq:HALO) announced completion of patient enrollment in the Phase III pivotal study of GAMMAGARD LIQUID [Immune Globulin Intravenous (Human) 10%] (also known as KIOVIG outside of the United States) with rHuPH20 (recombinant human hyaluronidase enzyme) for the treatment of primary immunodeficiency disorder (PID). Patients will receive monthly subcutaneous (SC) injections of Halozyme's rHuPH20 with Baxter's GAMMAGARD LIQUID. "The achievement of complete Phase III enrollment is an important milestone of Baxter's work with Halozyme to offer patients more advanced treatment options," said Hartmut J....
Source: Biotech Business Week (2009-07-27)
|
